rs777686211
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_001384732.1(CPLANE1):βc.1819delTβ(p.Tyr607fs) variant causes a frameshift change. The variant allele was found at a frequency of 0.000178 in 1,539,856 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (β β ). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: π 0.00017 ( 0 hom., cov: 32)
Exomes π: 0.00018 ( 0 hom. )
Consequence
CPLANE1
NM_001384732.1 frameshift
NM_001384732.1 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 4.24
Genes affected
CPLANE1 (HGNC:25801): (ciliogenesis and planar polarity effector complex subunit 1) The protein encoded by this gene has putative coiled-coil domains and may be a transmembrane protein. Defects in this gene are a cause of Joubert syndrome (JBTS). [provided by RefSeq, May 2012]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 5-37226775-TA-T is Pathogenic according to our data. Variant chr5-37226775-TA-T is described in ClinVar as [Likely_pathogenic]. Clinvar id is 217590.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr5-37226775-TA-T is described in Lovd as [Pathogenic]. Variant chr5-37226775-TA-T is described in Lovd as [Likely_pathogenic]. Variant chr5-37226775-TA-T is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CPLANE1 | NM_001384732.1 | c.1819delT | p.Tyr607fs | frameshift_variant | 12/53 | ENST00000651892.2 | NP_001371661.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CPLANE1 | ENST00000651892.2 | c.1819delT | p.Tyr607fs | frameshift_variant | 12/53 | NM_001384732.1 | ENSP00000498265.2 |
Frequencies
GnomAD3 genomes AF: 0.000171 AC: 26AN: 152060Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
26
AN:
152060
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000161 AC: 23AN: 142536Hom.: 0 AF XY: 0.000226 AC XY: 17AN XY: 75282
GnomAD3 exomes
AF:
AC:
23
AN:
142536
Hom.:
AF XY:
AC XY:
17
AN XY:
75282
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000179 AC: 248AN: 1387796Hom.: 0 Cov.: 32 AF XY: 0.000196 AC XY: 134AN XY: 683914
GnomAD4 exome
AF:
AC:
248
AN:
1387796
Hom.:
Cov.:
32
AF XY:
AC XY:
134
AN XY:
683914
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000171 AC: 26AN: 152060Hom.: 0 Cov.: 32 AF XY: 0.000135 AC XY: 10AN XY: 74304
GnomAD4 genome
AF:
AC:
26
AN:
152060
Hom.:
Cov.:
32
AF XY:
AC XY:
10
AN XY:
74304
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:18
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:6
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Feb 07, 2024 | Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 28125082, 34008892, 26092869, 34313030, Shelby[2022]casereport) - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jun 01, 2024 | CPLANE1: PVS1, PM2, PM3 - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 13, 2021 | This sequence change creates a premature translational stop signal (p.Tyr607Thrfs*6) in the CPLANE1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CPLANE1 are known to be pathogenic (PMID: 24178751, 26092869). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This premature translational stop signal has been observed in individuals with Joubert syndrome (PMID: 26092869, 28125082). ClinVar contains an entry for this variant (Variation ID: 217590). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Clinical Genetics Laboratory, Skane University Hospital Lund | Sep 23, 2022 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
Joubert syndrome 17 Pathogenic:5
Likely pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Jan 01, 2019 | This variant was identified as compound heterozygous. - |
Pathogenic, criteria provided, single submitter | research | UW Hindbrain Malformation Research Program, University of Washington | Feb 23, 2015 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Mendelics | Sep 15, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Aug 26, 2015 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory of Medical Genetics, National & Kapodistrian University of Athens | Aug 10, 2021 | PVS1, PM2, PP3, PP5 - |
Orofaciodigital syndrome type 6;C3553264:Joubert syndrome 17 Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | New York Genome Center | Feb 05, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Jun 30, 2021 | - - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 02, 2021 | The c.1819delT (p.Y607Tfs*6) alteration, located in exon 12 (coding exon 11) of the C5orf42 gene, consists of a deletion of one nucleotide at position 1819, causing a translational frameshift with a predicted alternate stop codon after 6 amino acids. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. This alteration has been reported in the compound heterozygous state with a second C5orf42 alteration in a patient with Joubert syndrome (Bachmann-Gagescu, 2015). Based on the available evidence, this alteration is classified as pathogenic. - |
Nephronophthisis Pathogenic:1
Likely pathogenic, no assertion criteria provided | clinical testing | Sydney Genome Diagnostics, Children's Hospital Westmead | May 31, 2018 | This patient is heterozygous for a likely pathogenic variant, c.1819del, in the C5orf42 gene. c.1819del (dbSNP: rs777686211) has been reported in the ExAC database (http://exac.broadinstitute.org/) with a low allele frequency of 0.024% (5/20526 alleles) and has also been reported as a compound heterozygous variant in a patient with Joubert syndrome (Bachmann-Gagescu et al. J.Med.Genet 2015; 52:514-522). This frameshifting variant is predicted to create a premature stop codon (p.Tyr607Thrfs*6) and may result in a null allele due to nonsense-mediated mRNA decay. This variant is considered to be a likely pathogenic according to the ACMG guidelines. - |
Jaundice;C0557874:Global developmental delay Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Centre for Mendelian Genomics, University Medical Centre Ljubljana | Nov 28, 2013 | - - |
Orofaciodigital syndrome type 6 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Centre for Mendelian Genomics, University Medical Centre Ljubljana | Apr 18, 2019 | This variant was classified as: Pathogenic. The following ACMG criteria were applied in classifying this variant: PVS1,PM2,PP5. - |
CPLANE1-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jan 08, 2024 | The CPLANE1 c.1819delT variant is predicted to result in a frameshift and premature protein termination (p.Tyr607Thrfs*6). This variant has previously been reported in the compound heterozygous state in individuals with Joubert syndrome (Bachmann-Gagescu et al. 2015. PubMed ID: 26092869; Table 1, Vilboux T et al 2017. PubMed ID: 28125082). This variant is reported in 0.024% of alleles in individuals of European (Non-Finnish) descent in gnomAD. Frameshift variants in CPLANE1 are expected to be pathogenic. This variant is interpreted as pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at